title: Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
abstract: The FDA has recently transferred jurisdiction for the regulation of certain biopharmaceuticals from the Center for Biologics, Evaluation and Research to the Center for Drugs, Evaluation and Research, where they will be reviewed in the same FDA divisions as are traditional pharmaceutical agents. With this transfer, sponsors of investigational biopharmaceuticals should expect changes in the regulatory requirements the FDA imposes on the clinical development plans, including an increase in the size and number of pivotal studies; more consistent requirements for conducting preclinical tests in two animal species; increased emphasis on organ structure and function as components of primary endpoints; more emphasis on characterizing dose-ranging and pharmacology; more intense scrutinizing of product advertising; and decreased direct communication with the review team.
authors.affiliation: Tekgenics, Inc., 3901 Point Road, Mobile, AL 36619, USA. wds@tekgenics.org
authors.forename: William D
authors.initials: WD
authors.lastname: Schwieterman
mesh_terms: D001688:Biological Products; D017277:Drug Approval; D007880:Legislation, Drug; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence / Q000458:organization & administration*
chemical_list: D001688:Biological Products